Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice

Movement Disorders

Volumn 32, Issue 4, 2017, Pages 538-548

  Perez, Xiomara A ^a   Zhang, Danhui ^a   Bordia, Tanuja ^a   Quik, Maryka ^a  

^a SRI INTERNATIONAL   (United States)

Author keywords

D1 receptor; dyskinesia; levodopa; medium spiny neuron

Indexed keywords

BENSERAZIDE; CHANNELRHODOPSIN2; DOPAMINE 1 RECEPTOR; DOPAMINE TRANSPORTER; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE; OXIDOPAMINE; RHODOPSIN; UNCLASSIFIED DRUG; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID ISOPROPYL ESTER; ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; CHANNELRHODOPSIN 2, MOUSE; COCAINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DYSKINESIA; ENZYME PHOSPHORYLATION; FEMALE; IN VIVO STUDY; MALE; MEDIUM SPINY NEURON; MOUSE; NERVE CELL STIMULATION; NEUROMODULATION; NONHUMAN; OPTOGENETICS; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS EXPRESSION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; CYTOLOGY; DIAGNOSTIC IMAGING; DISEASE MODEL; DYSKINESIAS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NERVE CELL; PARKINSONIAN DISORDERS; PATHOLOGY; PHYSIOLOGY; RADIATION RESPONSE; TRANSGENIC MOUSE;

ANIMALS; ANTIPARKINSON AGENTS; COCAINE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DYSKINESIAS; FEMALE; GENE EXPRESSION REGULATION; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RECEPTORS, DOPAMINE D1; RHODOPSIN; SYMPATHOLYTICS;

EID: 85014185462     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26955     Document Type: Article

References (60)

1. Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev 2013;65(1):171–222.
2. Kreitzer AC, Malenka RC. Striatal plasticity and basal ganglia circuit function. Neuron 2008;60(4):543–554.
3. Bastide MF, Meissner WG, Picconi B, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Prog Neurobiol 2015;132:96–168.
4. Feyder M, Bonito-Oliva A, Fisone G. L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front Behav Neurosci 2011;5:71.
5. Deniau JM, Mailly P, Maurice N, Charpier S. The pars reticulata of the substantia nigra: a window to basal ganglia output. Prog Brain Res 2007;160:151–172.
6. Freeze BS, Kravitz AV, Hammack N, Berke JD, Kreitzer AC. Control of basal ganglia output by direct and indirect pathway projection neurons. J Neurosci 2013;33(47):18531–18539.
7. Kravitz AV, Freeze BS, Parker PR, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 2010;466(7306):622–626.
8. Cazorla M, Kang UJ, Kellendonk C. Balancing the basal ganglia circuitry: a possible new role for dopamine D2 receptors in health and disease. Mov Disord 2015;30(7):895–903.
9. Cui G, Jun SB, Jin X, et al. Concurrent activation of striatal direct and indirect pathways during action initiation. Nature 2013;494(7436):238–242.
10. Durieux PF, Schiffmann SN, de Kerchove d'Exaerde A. Differential regulation of motor control and response to dopaminergic drugs by D1R and D2R neurons in distinct dorsal striatum subregions. EMBO J 2012;31(3):640–653.
11. Cenci MA, Konradi C. Maladaptive striatal plasticity in l-DOPA-induced dyskinesia. Prog Brain Res 2010;183C:209–233.
12. Fieblinger T, Graves SM, Sebel LE, et al. Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. Nat Commun 2014;5:5316.
13. Guigoni C, Doudnikoff E, Li Q, Bloch B, Bezard E. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol Dis 2007;26(2):452–463.
14. Aubert I, Guigoni C, Hakansson K, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005;57(1):17–26.
15. Breese GR, Duncan GE, Napier TC, Bondy SC, Iorio LC, Mueller RA. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J Pharmacol Exp Ther 1987;240(1):167–176.
16. Savasta M, Dubois A, Benavides J, Scatton B. Different plasticity changes in D1 and D2 receptors in rat striatal subregions following impairment of dopaminergic transmission. Neurosci Lett 1988;85(1):119–124.
17. Warre R, Thiele S, Talwar S, et al. Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism. Neurobiol Dis 2011;41(3):591–604.
18. Suarez LM, Solis O, Aguado C, Lujan R, Moratalla R. L-DOPA oppositely regulates synaptic strength and spine morphology in D1 and D2 striatal projection neurons in dyskinesia [published online ahead of print 2016]. Cereb Cortex.
19. Suarez LM, Solis O, Carames JM, et al. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice. Biol Psychiatry 2014;75(9):711–722.
20. Berthet A, Porras G, Doudnikoff E, et al. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J Neurosci 2009;29(15):4829–4835.
21. Delfino M, Kalisch R, Czisch M, et al. Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology 2007;32(9):1911–1921.
22. Grondin R, Goulet M, Morissette M, Bedard PJ, Di Paolo T. Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958. Eur J Pharmacol 1999;378(3):259–263.
23. Taylor JL, Bishop C, Walker PD. Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol Biochem Behav 2005;81(4):887–893.
24. Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 2007;62(7):800–810.
25. Darmopil S, Martin AB, De Diego IR, Ares S, Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 2009;66(6):603–613.
26. Revy D, Jaouen F, Salin P, et al. Cellular and behavioral outcomes of dorsal striatonigral neuron ablation: new insights into striatal functions. Neuropsychopharmacology 2014;39(11):2662–2672.
27. Engeln M, Bastide MF, Toulme E, et al. Selective inactivation of striatal FosB/DeltaFosB-expressing neurons alleviates L-DOPA-induced dyskinesia. Biol Psychiatry 2016;79(5):354–361.
28. Mela F, Marti M, Bido S, Cenci MA, Morari M. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. Neurobiol Dis 2012;45(1):573–582.
29. Thiele SL, Chen B, Lo C, et al. Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models. Neurobiol Dis 2014;71:334–344.
30. Murer MG, Moratalla R. Striatal signaling in L-DOPA-induced dyskinesia: common mechanisms with drug abuse and long term memory involving D1 dopamine receptor stimulation. Front Neuroanat 2011;5:51.
31. Bagetta V, Sgobio C, Pendolino V, et al. Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease. J Neurosci 2012;32(49):17921–17931.
32. Larramendy C, Taravini IR, Saborido MD, Ferrario JE, Murer MG, Gershanik OS. Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism. Behav Brain Res 2008;194(1):44–51.
33. Grondin R, Doan VD, Gregoire L, Bedard PJ. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 1999;52(4):771–776.
34. Lindgren HS, Ohlin KE, Cenci MA. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. Neuropsychopharmacology 2009;34(12):2477–2488.
35. Gold SJ, Hoang CV, Potts BW, et al. RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J Neurosci 2007;27(52):14338–14348.
36. Cenci MA, Lundblad M. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Proto Neurosci 2007;Chapter 9:Unit 9.25.
37. Huang LZ, Grady SR, Quik M. Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors. J Pharmacol Exp Ther 2011;338(3):932–941.
38. Bordia T, Perez XA, Heiss JE, Zhang D, Quik M. Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias. Neurobiol Dis 2016;91:47–58.
39. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000;39(5):777–787.
40. Bordia T, McGregor M, McIntosh JM, Drenan RM, Quik M. Evidence for a role for alpha6 (*) nAChRs in l-dopa-induced dyskinesias using Parkinsonian alpha6 (*) nAChR gain-of-function mice. Neuroscience 2015;295:187–197.
41. Quik M, Campos C, Bordia T, et al. alpha4beta2 nicotinic receptors play a role in the nAChR-mediated decline in l-dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology 2013;71:191–203.
42. Quik M, Campos C, Grady SR. Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice. Biochem Pharmacol 2013;86(8):1153–1162.
43. Quik M, Sum JD, Whiteaker P, et al. Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol Pharmacol 2003;63(5):1169–1179.
44. Santini E, Alcacer C, Cacciatore S, et al. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem 2009;108(3):621–633.
45. Santini E, Valjent E, Usiello A, et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 2007;27(26):6995–7005.
46. Pavon N, Martin AB, Mendialdua A, Moratalla R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 2006;59(1):64–74.
47. Solís, O., Garcia-Montes, J.R., González-Granillo, A., Xu, M., Moratalla, R., Dopamine D3 receptor modulates L-DOPA-induced dyskinesia by targeting D1 receptor-mediated striatal signaling. Cereb. Cortex, 2015, 27(1): 435-446.
48. Kumar R, Riddle LR, Griffin SA, et al. Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology 2009;56(6–7):956–969.
49. Borgkvist A, Avegno EM, Wong MY, et al. Loss of striatonigral GABAergic presynaptic inhibition enables motor sensitization in parkinsonian mice. Neuron 2015;87(5):976–988.
50. Mango D, Bonito-Oliva A, Ledonne A, et al. Phosphodiesterase 10A controls D1-mediated facilitation of GABA release from striato-nigral projections under normal and dopamine-depleted conditions. Neuropharmacology 2014;76(pt A):127–136.
51. Rangel-Barajas C, Silva I, Lopez-Santiago LM, Aceves J, Erlij D, Floran B. L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata. Neurobiol Dis 2011;41(1):51–61.
52. Gerfen CR, Miyachi S, Paletzki R, Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 2002;22(12):5042–5054.
53. Santini E, Heiman M, Greengard P, Valjent E, Fisone G. Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Sci Signal 2009;2(80):ra36.
54. Andersson M, Hilbertson A, Cenci MA. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 1999;6(6):461–474.
55. Gonzalez-Aparicio R, Moratalla R. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson s disease. Neurobiol Dis 2014;62:416–425.
56. Taverna S, Ilijic E, Surmeier DJ. Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease. J Neurosci 2008;28(21):5504–5512.
57. Czubayko U, Plenz D. Fast synaptic transmission between striatal spiny projection neurons. Proc Natl Acad Sci U S A 2002;99(24):15764–15769.
58. Gustafson N, Gireesh-Dharmaraj E, Czubayko U, Blackwell KT, Plenz D. A comparative voltage and current-clamp analysis of feedback and feedforward synaptic transmission in the striatal microcircuit in vitro. J Neurophysiol 2006;95(2):737–752.
59. Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M. Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci 2014;17(8):1022–1030.
60. Shen W, Flajolet M, Greengard P, Surmeier DJ. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008;321(5890):848–851.